These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Cheng Z; Gong Y; Ma Y; Lu K; Lu X; Pierce LA; Thompson RC; Muller S; Knapp S; Wang J Clin Cancer Res; 2013 Apr; 19(7):1748-59. PubMed ID: 23403638 [TBL] [Abstract][Full Text] [Related]
10. BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells. Alghamdi S; Khan I; Beeravolu N; McKee C; Thibodeau B; Wilson G; Chaudhry GR Stem Cell Res Ther; 2016 Feb; 7():22. PubMed ID: 26830473 [TBL] [Abstract][Full Text] [Related]
11. [Effects of BET Bromodomain Inhibitor JQ1 on Double-Expressor Lymphoma Cell Lines and Its Mechanism]. Chen XY; Yan X; Song BY; Sun J; Mu LJ; Li WP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1094-1100. PubMed ID: 35981367 [TBL] [Abstract][Full Text] [Related]
12. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185 [TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580 [TBL] [Abstract][Full Text] [Related]
16. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells. Zanellato I; Colangelo D; Osella D Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341 [TBL] [Abstract][Full Text] [Related]
18. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological Targeting of BET Bromodomains Inhibits Lens Fibrosis via Downregulation of MYC Expression. Wang X; Wang B; Zhao N; Wang C; Huang M; Chen B; Chen J; Sun Y; Xiong L; Huang S; Liu Y Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4748-4758. PubMed ID: 31731295 [TBL] [Abstract][Full Text] [Related]